| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.8 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |